74
Participants
Start Date
February 8, 2017
Primary Completion Date
January 28, 2021
Study Completion Date
April 29, 2022
Parsaclisib
Up to 3 oral once a day (QD) doses of parsaclisib. Doses will be taken once daily for 8 weeks, followed by once weekly dosing at the same dose level.
Parsaclisib
Two recommended oral QD doses of parsaclisib. Once daily doses of parsaclisib will be taken for 8 weeks, followed by once weekly dosing at the same dose level.
Ruxolitinib
The dose of ruxolitinib will be that which the subjects had been taking for at least 8 weeks before the first dose of parsaclisib.
Parsaclisib
20 mg oral QD dose of parsaclisib for 8 weeks. After 8 weeks patients will take either 20 mg once weekly or 5 mg once daily.
Parsaclisib
"2 dose strategies will be compared:~1. 5 mg parsaclisib beginning on Day 1 until end of treatment.~2. 20 mg oral QD dose of parsaclisib for 8 weeks; after 8 weeks patients will take 5 mg once daily."
Mount Sinai School of Medicine, New York
Columbia University Medical Center, New York
Memorial Sloan Kettering Cancer Center, New York
Montefiore Medical Center, The Bronx
Roswell Park Cancer Institute, Buffalo
Georgetown University Hospital, Washington D.C.
Cancer Center For Blood Disorders, Bethesda
Saint Agnes Hospital, Baltimore
Emory University, Atlanta
Shands Hospital, Gainesville
Birmingham Hematology & Oncolgy Associates Llc, Birmingham
Rush University Medical Center, Nashville
Norton Cancer Institute, Louisville
Cleveland Clinic, Cleveland
Oncology Hematology Care, Inc., Cincinnati
Indiana Blood and Marrow Transplantation, Indianapolis
McFarland Clinic, Ames
University of Chicago Medical Center, Chicago
Washington University School of Medicine, St Louis
University of Kansas Cancer Center, Westwood
Baylor Scott and White Research Institute, Dallas
Md Anderson Cancer Center, Houston
Renovatio Clinical Consultants Llc, The Woodlands
Cancer Care Centers of South Texas, San Antonio
Va Salt Lake City Health Care System, Salt Lake City
Mayo Clinic Arizona, Scottsdale
New Mexico Cancer Care Alliance, Albuquerque
University of Southern California, Los Angeles
UCLA School of Medicine, Los Angeles
City of Hope National Medical Center, Duarte
California Cancer Assoc. for Research and Excellence, San Marcos
Pcr Oncology, Pismo Beach
California Cancer Associates For Research and Excellence, Fresno
Alta Bates Medical Center, Berkeley
Oregon Health & Science University, Portland
Vista Oncology Inc Ps, Olympia
Massachusetts General Hospital, Boston
Summit Medical Group, Florham Park
Hackensack University Medical Center, Hackensack
Lead Sponsor
Incyte Corporation
INDUSTRY